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Abstract
Introduction: Steroids are a useful component of combination chemotherapy or as a single agent in the treatment of
haematological disorders even though there are adverse effects associated with its use.
Methods: We report four patients who developed diabetes mellitus (DM) during treatment with steroids for haematological
disorders despite a negative history of DM.
Results: The mean age of the patients was 55yrs and DM was diagnosed by fasting plasma glucose (FPG) after a cumulative
steroid dose of  500-1800mg.
Conclusion: It is necessary to have a baseline and frequent FPG in patients who are considered for combination chemotherapy
which include steroid since the development of DM does not appear to be dose dependent or related to history of DM in
the patient or family.
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Combination chemotherapy is useful in the
management of haematological malignancies and this
evolved from the use of single agents in order to
overcome drug resistance. Attention was drawn to
the benefit of steroids in the treatment of lymphoid
malignancy by the observation that it induces
regression of lymphoid tumours in man1.
Subsequently, massive doses of  steroids were used
in the management of haematological malignancies
but the associated side effects preclude its routine
use2. The use of physiological doses with treatable
side effects heralded its use in combination
chemotherapy3.
Steroids continued to be used as an adjuvant
in most of these drug combinations and in pulses
despite known complications associated with its use.
Steroid use is not only limited to haematological
disorders but it is also useful as an
immunosuppressant in other disease conditions and
especially now in transplantation medicine. Adverse
effects associated with the use of steroids include
gastritis, glaucoma, hypertension and impaired
glucose tolerance, there are reports on these adverse
effects in its use in the treatment of many disease
conditions4-6 but we are not aware of any report on
the side effects of steroids in combination
chemotherapy for haematological disorders.
We discuss four patients who developed
Diabetes Mellitus (DM) after the use of combination
chemotherapy which included Prednisolone for the
treatment of  haematological disorders.
Patients
The age range of the patients was 43-66 years, with
a mean of 55 years and included three female and
one male. Two of  the patients were managed for
lymphoma while the other two were managed for
chronic lymphocytic leukaemia and aplastic anaemia.
The lymphoma patients had combination
chemotherapy with Cyclophosphomide,
Hydroxydaunorubicin, Oncovin and Prednisolone
(CHOP) while the patient with chronic leukaemia
had Cyclophosphmide, Oncovin and Prednisolone
(CVP). The patient with apalastic anaemia had
Prednisolone alone. All the patients on combination
chemotherapy received 60mg of Prednisolone daily
for five days with each cycle of the chemotherapy
while the patient with aplastic anemia had same dose
daily until the diagnosis of DM after which the dose
was reduced to 30mg daily.  All the patients denied
any history of  diabetes in the past in the family. Two
of  the patients had normal fasting plasma glucose
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(FPG) before commencing chemotherapy but the
other two patients did not have the test done. The
diagnosis of diabetes mellitus was based on FPG
which is > 126mg/dl or a random glucose
concentration exceeding 200 mg/dL at least twice
after beginning steroid treatment and these patients
had FPGs between 147-566mg/dl.
Normoglycaemia was achieved with insulin therapy
and patients were maintained on oral glucose
lowering agents. There was poor response to
chemotherapy in all the patients. One of  the patients
with lymphoma was diagnosed as hypertensive two
months before the diagnosis of lymphoma while
the patient with aplastic anaemia also developed
hypertension while on steroid therapy. Others had
no history of hypertension and remained
normotensive thereafter.
Discussion
Diabetes is a known complication of steroid therapy
whether as a single agent or in combination with
other drugs as seen in our group of  patients. The
diabetogenic effect of glucocorticoids is said to be
determined by dose, duration of  administration and
type of steroid. Diabetes has also been associated
with L- asparaginase in combination chemotherapy
when used in the treatment of acute leukaemia and
often it is used along with steroid 7,8 but the diabetes
resulting from the use of L-asparaginase is transient.
The transient effect may be because the
reported cases are children and also because it is used
for a short period as induction chemotherapy, in
contrast to our patients who are adults and in whom
the use of  steroid is for longer periods. This
complication was also observed in patients in the
middle age with a predilection for female (though
only four patients were seen), which is similar to what
was observed in a group of  patients treated with
steroid for varied respiratory diseases 4. A common
finding in cases of steroid induced diabetes mellitus
(SIDM) is that it appears not to be dose related and
risk factors are not readily identified even though
some studies have alluded to a higher prevalence in
people of black ancestry but this is yet to be
confirmed 9,10. The cumulative dose until the
diagnosis of DM ranged between 500-1800mg in
our group of patients while in the patients who
developed SIDM after treatment for respiratory
diseases the cumulative dose ranged between 940-
23590mg.
The patient with aplastic anaemia had the
steroid for less than ten days before DM was
confirmed but unfortunately he did not have a
baseline test done before the commencement of
steroid .He denied previous history of DM but the
early onset of  DM here may suggest that this patient
likely had a significant degree of glucose intolerance
prior to administration of  steroids. The other patients
had the treatment with steroid for between 2-6mths
before the onset of  DM suggesting that the length
of therapy before development of SIDM is highly
individualized and is affected by other risk factors.
Some reports have suggested that SIDM affects
persons in the older age group which a number of
the patients in the study fall into. This is due to the
decreased ability of the islets cells of Langerhans to
control insulin resistance induced by glucocorticoids
with increasing age.
The use of steroids in renal transplant
patients is also associated with DM as a side effect
even when used at low doses but the length of use
is longer (in years). The incidence of SIDM reduced
from 20% in a study that gave 5-7.5mg/day for
maintenance over a five year period 10 to 7% in
another study that prescribed 2.5mg/day for two
years 11. The non use of steroids as maintenance
agents is however being advocated for, in renal
transplant patients because of the associated side
effects 10. There is a need to consider the non use of
steroid in combination chemotherapy for
haematological disorder if SIDM is reported from
other centres and after a controlled trial confirms
the finding. It is also necessary to identify other risk
factors associated with the development of SIDM
while the role of age and ethnicity should be further
explored.
Physiologic doses are used in pulses in
combination chemotherapy for haematological
malignancies while low continuous doses are used
in renal transplant patients yet these patients still
develop SIDM. It is therefore evident that the dose,
whether as low continuous or in pulses does not
prevent the adverse effect of developing DM.
Conclusion
If possible, the removal of steroids or the use of
other immunosuppressant may be considered not
only for haematological disorders but also for chronic
disorders that require long term use of  steroids.
However, when steroids have to be used, there is a
need for frequent blood glucose monitoring, so that
rising blood glucose values can be detected early and
appropriate therapy instituted. We advocate that this
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should be done after each cycle or before the
commencement of another cycle.
Early intervention will prevent the onset of
acute complications of DM as well as possible long
term complications, thus reducing morbidity and
mortality associated with SIDM as a complication
of  therapy. Further prospective studies or
randomized controlled trials need to be carried out
to accurately outline the long term advantages and
disadvantages of steroid therapy in persons requiring
treatment with these drugs for survival.
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